Why is the Medlab (ASX:MDC) share price surging 8% today?

The Medlab (ASX: MDC) share price is rising today after the European Patent Office announced its intention to grant Nanocelle a patent.

The Medlab Clinical Ltd (ASX: MDC) share price is rising today after the European Patent Office announced its intention to grant the Australian company a patent for its Nanocelle technology.

The Medlab share price is up 8.33% today to 26 cents per share. 

Medlab is a medical research and development company that's gained a lot of publicity for its innovative medical use of THC, one of the psychoactive compounds in cannabis.

It largely focuses on THC and other cannabinoid products as pain-relievers, but the company is also engaged in researching and formulating novel biotherapeutics or new therapeutic medicines derived from natural organisms.

Its products aim to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity.

Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

What is Medlab's Nanocelle technology?

Medlab is currently focused on the development of Nanocelle technology that can increase the solubility of medicines. It does this through a sub-micron spray, which is administered to the membrane lining the inside of the mouth.

When sprayed, it provides faster and more effective absorption of active ingredients into the bloodstream, without the need for needles or pills.

Medlab considers Nanocelle "a commercially viable platform that offers unique opportunities for partnering with some of the biggest players in the pharma industry". It was behind considerable Medlab share price rises in February this year.

When the European Union grants Medlab's patent, it will be the second granted for Nanocelle, following receipt of an Australian patent in September 2020. Medlab has also filed patent applications in the United States, New Zealand, Singapore, Hong Kong and Canada.

What Medlab management said

Medlab CEO Dr Sean Hall said the patent was the next step in Nanocelle's expansion into worldwide markets.

Receiving notice of intent from the European Patent Office represents another important validation of our NanoCelle drug delivery platform, offering Nanocelle protection in one of the world's largest markets.

The grant will not only bolster the competitive advantage of our pharmaceutical and nutraceutical portfolio, it will also support our robust research and development pipeline and commercial partnering focus. We are delighted with this recognition.

Medlab share price snapshot

The Medlab share price has been on a rocky road, rising from 15 cents in July 2020 to more than 36 cents in January this year. It's gained 6% in 2021 so far but lost 8% over the past 12 months and is down 40% against the S&P/ASX 200 Index (ASX: XJO).

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »